RhumbLine Advisers’s Agios Pharmaceuticals AGIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.95M | Buy |
79,441
+6,072
| +8% | +$184K | ﹤0.01% | 1741 |
|
|
2026
Q1 | $2.48M | Sell |
73,369
-784
| -1% | -$22.2K | ﹤0.01% | 1746 |
|
|
2025
Q4 | $2.02M | Sell |
74,153
-13,549
| -15% | -$475K | ﹤0.01% | 1876 |
|
|
2025
Q3 | $3.52M | Sell |
87,702
-2,179
| -2% | -$82K | ﹤0.01% | 1602 |
|
|
2025
Q2 | $2.99M | Buy |
89,881
+3,039
| +3% | +$92.1K | ﹤0.01% | 1667 |
|
|
2025
Q1 | $2.54M | Sell |
86,842
-7,666
| -8% | -$254K | ﹤0.01% | 1693 |
|
|
2024
Q4 | $3.11M | Buy |
94,508
+285
| +0.3% | +$13.4K | ﹤0.01% | 1652 |
|
|
2024
Q3 | $4.19M | Sell |
94,223
-6,957
| -7% | -$316K | ﹤0.01% | 1521 |
|
|
2024
Q2 | $4.36M | Sell |
101,180
-970
| -0.9% | -$35K | ﹤0.01% | 1468 |
|
|
2024
Q1 | $2.99M | Buy |
102,150
+1,652
| +2% | +$44.2K | ﹤0.01% | 1692 |
|
|
2023
Q4 | $2.24M | Sell |
100,498
-1,624
| -2% | -$36.4K | ﹤0.01% | 1844 |
|
|
2023
Q3 | $2.53M | Buy |
102,122
+1,240
| +1% | +$32.8K | ﹤0.01% | 1748 |
|
|
2023
Q2 | $2.86M | Buy |
100,882
+9,477
| +10% | +$236K | ﹤0.01% | 1706 |
|
|
2023
Q1 | $2.1M | Buy |
91,405
+2,137
| +2% | +$56.8K | ﹤0.01% | 1782 |
|
|
2022
Q4 | $2.51M | Buy |
89,268
+2,322
| +3% | +$65.4K | ﹤0.01% | 1663 |
|
|
2022
Q3 | $2.46M | Buy |
86,946
+5,291
| +6% | +$142K | ﹤0.01% | 1644 |
|
|
2022
Q2 | $1.81M | Buy |
81,655
+6,199
| +8% | +$140K | ﹤0.01% | 1816 |
|
|
2022
Q1 | $2.2M | Sell |
75,456
-6,309
| -8% | -$193K | ﹤0.01% | 1768 |
|
|
2021
Q4 | $2.69M | Sell |
81,765
-4,239
| -5% | -$171K | ﹤0.01% | 1723 |
|
|
2021
Q3 | $3.97M | Sell |
86,004
-2,545
| -3% | -$123K | 0.01% | 1490 |
|
|
2021
Q2 | $4.88M | Buy |
88,549
+19,331
| +28% | +$1.08M | 0.01% | 1440 |
|
|
2021
Q1 | $3.57M | Sell |
69,218
-1,866
| -3% | -$92.4K | ﹤0.01% | 1595 |
|
|
2020
Q4 | $3.08M | Buy |
71,084
+3,430
| +5% | +$136K | ﹤0.01% | 1630 |
|
|
2020
Q3 | $2.37M | Sell |
67,654
-2,129
| -3% | -$93.3K | ﹤0.01% | 1579 |
|
|
2020
Q2 | $3.73M | Buy |
69,783
+5,916
| +9% | +$274K | 0.01% | 1373 |
|
|
2020
Q1 | $2.27M | Buy |
63,867
+15,281
| +31% | +$706K | ﹤0.01% | 1481 |
|
|
2019
Q4 | $2.32M | Buy |
48,586
+4,086
| +9% | +$154K | ﹤0.01% | 1717 |
|
|
2019
Q3 | $1.44M | Buy |
44,500
+1,368
| +3% | +$56.6K | ﹤0.01% | 1881 |
|
|
2019
Q2 | $2.15M | Sell |
43,132
-7,431
| -15% | -$397K | ﹤0.01% | 1705 |
|
|
2019
Q1 | $3.41M | Sell |
50,563
-245
| -0.5% | -$14.3K | 0.01% | 1394 |
|
|
2018
Q4 | $2.34M | Sell |
50,808
-1,808
| -3% | -$112K | 0.01% | 1544 |
|
|
2018
Q3 | $4.06M | Sell |
52,616
-746
| -1% | -$60K | 0.01% | 1243 |
|
|
2018
Q2 | $4.5M | Buy |
53,362
+3,211
| +6% | +$280K | 0.01% | 1169 |
|
|
2018
Q1 | $4.1M | Buy |
50,151
+5,029
| +11% | +$389K | 0.01% | 1168 |
|
|
2017
Q4 | $2.58M | Sell |
45,122
-663
| -1% | -$41.7K | 0.01% | 1478 |
|
|
2017
Q3 | $3.06M | Sell |
45,785
-497
| -1% | -$29.9K | 0.01% | 1337 |
|
|
2017
Q2 | $2.38M | Buy |
46,282
+9,374
| +25% | +$479K | 0.01% | 1470 |
|
|
2017
Q1 | $2.15M | Buy |
36,908
+961
| +3% | +$46.1K | 0.01% | 1508 |
|
|
2016
Q4 | $1.5M | Buy |
35,947
+6,147
| +21% | +$323K | ﹤0.01% | 1617 |
|
|
2016
Q3 | $1.57M | Buy |
29,800
+985
| +3% | +$42.9K | ﹤0.01% | 1563 |
|
|
2016
Q2 | $1.21M | Buy |
28,815
+4,574
| +19% | +$226K | ﹤0.01% | 1666 |
|
|
2016
Q1 | $984K | Sell |
24,241
-706
| -3% | -$30.2K | ﹤0.01% | 1811 |
|
|
2015
Q4 | $1.62M | Buy |
24,947
+605
| +2% | +$39.7K | 0.01% | 1497 |
|
|
2015
Q3 | $1.72M | Buy |
24,342
+736
| +3% | +$71.9K | 0.01% | 1411 |
|
|
2015
Q2 | $2.62M | Buy |
23,606
+7,880
| +50% | +$849K | 0.01% | 1231 |
|
|
2015
Q1 | $1.48M | Buy |
15,726
+3,005
| +24% | +$337K | ﹤0.01% | 1606 |
|
|
2014
Q4 | $1.43M | Buy |
12,721
+1,371
| +12% | +$122K | ﹤0.01% | 1571 |
|
|
2014
Q3 | $696K | Sell |
11,350
-640
| -5% | -$27.6K | ﹤0.01% | 2005 |
|
|
2014
Q2 | $549K | Buy |
+11,990
| New | +$489K | ﹤0.01% | 2218 |
|
Other funds holding AGIO
FCM
LCM
AC
EAM
NAMI
RhumbLine Advisers's AGIO Position: Q2 2026 in Review
RhumbLine Advisers increased its Agios Pharmaceuticals (AGIO) stake by 8.3% in Q2 2026, buying an estimated $184K and bringing the position to 79,441 shares worth $2.95M. The position accounts for ﹤0.01% of the portfolio, ranked #1741.
RhumbLine Advisers first reported a position in AGIO in Q2 2014 and has held it in 49 quarters since. The position peaked at $4.88M in Q2 2021. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.
- RhumbLine Advisers held 79,441 shares of Agios Pharmaceuticals worth $2.95M as of Q2 2026.
- RhumbLine Advisers bought 6,072 Agios Pharmaceuticals shares in Q2 2026, an estimated $184K.
- Agios Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1741 holding.
- RhumbLine Advisers first reported a position in Agios Pharmaceuticals in Q2 2014 and has held it in 49 quarters since.
- RhumbLine Advisers's Agios Pharmaceuticals position peaked at $4.88M in Q2 2021.
- 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.